Close

New NIH COVID-19 Funding Announcements

NIH released three new notices regarding funding opportunities for SARS-CoV-2 and COVID-19 research.
See details below, and also check the MIDAS COVID-19 site for more news and information about COVID-19.
 
NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. Applications for this initiative should be submitted through one of the funding opportunity announcements listed below, for deadlines starting April 5, 2020. Contact Dr. Erik Stemmy (erik.stemmy@nih.gov) or Wolfgang Leitner (wleitner@niaid.nih.gov) at NIAID for more information.
 
  • PA-19-052: NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
  • PA-19-053: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  • PA-18-591: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp – Clinical Trial Optional)
  • PA-19-056: NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-19-272: PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
  • PA-19-270: PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
 
Researchers can request competitive revisions to existing NIAID grants, for COVID-19 research. NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. To apply, use  PA-20-135; Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional). For more information, contact Dr. Diane Post (postd@niaid.nih.gov) or Wolfgang Leitner (wleitner@niaid.nih.gov) at NIAID. 
 
Researchers can request competitive revisions to existing NIGMS grants, for COVID-19 research. NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest: (1) Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants); (2) Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only); (3) Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only). To apply, use  PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional). For more information, contact Dr. Dan Janes (daniel.janes@nih.gov) or Dmitriy Krepkiy (krepkiyd@mail.nih.gov) at NIGMS.